Name | JNJ-1661010 |
Description | JNJ-1661010 (Takeda-25) is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2. |
In vitro | Preincubation of JNJ-1661010 with fatty acid amide hydrolase showed a slow reversible interaction between JNJ-1661010 and the active site, which was catalyzed by high temperature. In the hydrophobic channel, JNJ-1661010 could dock with phenylthiadiazole, and in the hydrophilic pocket of fatty acid amide hydrolase, it docked with phenylurea. |
In vivo | Preincubation of JNJ-1661010 with fatty acid amide hydrolase showed a slow reversible interaction between JNJ-1661010 and the active site, which was catalyzed by high temperature. In the hydrophobic channel, JNJ-1661010 could dock with phenylthiadiazole, and in the hydrophilic pocket of fatty acid amide hydrolase, it docked with phenylurea. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 3.7 mg/mL (10 mM) DMSO : 36.6 mg/mL (100 mM)
|
Keywords | broad-spectrum | acid | inhibit | hydrolase | barrier | FAAH | Takeda25 | Fatty acid amide hydrolase | amide | Takeda 25 | blood-brain | Inhibitor | JNJ-1661010 | analgesics | Fatty |
Inhibitors Related | WWL 154 | VU534 | Biochanin A | 2-Chlorophenylboronic acid | AA38-3 | Carprofen | Dual FAAH/sEH-IN-1 | FAAH inhibitor 1 | PDP-EA | PF 750 | MM-433593 | JNJ-42165279 |
Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library |